The Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, was briefed yesterday, Saturday, on advanced manufacturing technologies for biological and genetic medicines at a specialized factory in Tianjin, China. These techniques are considered modern innovations in the medical field, aimed at providing treatments for many incurable diseases.

Dr. Aljadhey undertook a visit to the Institute of Hematology & Blood Diseases Hospital in Tianjin, a preeminent institution in China dedicated to the treatment of blood diseases. The hospital, which boasts a capacity of 1,000 beds equipped with the latest technologies and advanced laboratories, is actively engaged in both research and clinical studies. Dr. Aljadhey delved into their ongoing clinical trials and explored the utilization of genetic medicines in cancer therapy. The hospital is plays a key role in medical innovation, developing novel treatments and personalized therapeutic regimens based on genetic medicine, thereby providing efficacious solutions for cancer and various blood diseases.

These visits are aims to enhance the quality and safety of imported medicines, reflecting a broader initiative to strengthen international cooperation and share experiences in the health sector. They also underscore the SFDA's commitment to improving the quality of therapeutic techniques used in the Kingdom of Saudi Arabia, ultimately elevating healthcare standards for the community and promoting global collaboration.

This was part of the SFDA CEO’s visit to China to sign an MoU with China’s National Medical Products Administration (NMPA) and lead the Kingdom’s delegation at the 8th Shenzhen Food Safety Forum, which will be held from November 5 to 6, 2024.